Ceapro Inc (TSX VENTURE:CZO), a Canadian growth-stage biotechnology company focused on the development and commercialisation of active ingredients for healthcare and cosmetic industries, announced yesterday its financial results for the six-month period ended 30 June 2016.
The company reported total sales at USD8,231,000 in the first half of 2016, compared with USD4,154,000 in the same period in 2015. A 98% increase for the first six month period.
Income from operations before tax was USD4,092,000 in H1 2016, compared to USD428,000 in 2015.
The firm posted net profit of USD2,849,000 in the first half of 2016 against USD464,000 in the year-ago period.
Danaher Corporation announces quarterly cash dividend
Abbott announces quarterly common dividend
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva